Highly efficient methods that are now available allow for the genetic modification of cells that compose the vessel wall. The application of these gene transfer systems are already providing information that has enhanced our understanding of a variety of cellular processes relating to vascular biology. Recent experimental results using this technology also hold promise for more powerful therapeutic options in the treatment of vascular disease. This review discusses the most commonly used methods of gene transfer and details some current applications of these methodologies in animal models of vascular dis.
ease. It is important to emphasize at the onset, however, that there remains a large gap at present between the promise and the reality of gene therapy approaches. Many questions regarding safety, selectivity, and efficacy remain unanswered and untested. What follows is a highly selective overview of some approaches being used, with particular emphasis on gene therapy approaches to restenosis.
METHODS OF GENE TRANSFER
A variety of gene transfer techniques are available, each with differing efficiencies of transduction and each with distinct advantages and disadvantages. A description of some of the various modalities most often used, along with a selective set of examples of their use in animal models of vascular disease, is presented in Table  1 .
Naked DNA Direct gene transfer using "naked DNA" has been demonstrated to produce a low but detectable rate of transgene expression, particularly in skeletal and cardiac muscle (1-3). In a high flow state, such as the vessel wall, direct gene transfer appears to be enhanced by impregnating the DNA onto a hydrogel-coated catheter, which presumably allows for longer contact between the DNA and the vasculature (4) . Efficiencies are very low (usually less than 1%), although this method may be sufficient for certain applications, such as the secretion of potent growth factors for the stimulation of angiogenesis (5) . Indeed, the first approved human protocol for vascular gene transfer involves the direct transfer of DNA for the gene encoding vascular endothelial growth factor (VEGF). With this method of delivery the transgene is not integrated into the cell's DNA, thereby avoiding the potential problem of insertional mutagenesis (see below) but having the disadvantage of short-term gene expression because the transgene will be lost or diluted after cell division.
Liposomes
To improve efficiency of gene transfer, DNA has been incorporated in a variety of lipid vesicle formulations generically known as liposomes.
Although this approach does increase gene transfer efficiency, it also routinely results in efficiencies below 1% (6) (7) (8) (9) (10) . Further improvement appears to result by producing complexes of liposomes with particles of the hemagglutinating virus of Japan, denoted as HVJ-liposomes (11) .
Retroviruses
Retroviral vectors have also been used to modify the vessel wall, but appear to provide no significant benefit in efficiency over liposomal methods (6, 12 (58) be effective in the normal vessel wall where both endothehal and SMC turnover are low.
One intriguing use of retroviral vectors is to infect smooth muscle (14) (15) (16) Fig. 2A 
GENE THERAPY FOR RESTENOSIS
The ability to target high-level gene expression to the arterial wall suggests that such methods will be useful to understand and potentially treat a variety of vascular diseases. (31, 32) .
A similar approach could be used to interrupt essential elements regulating the cell cycle that constitutes the final common pathway for cell replication.
Included among these candidate genes would be members of the Rb family, the cyclins and their associated kinases, the emerging family of cyclin-dependent kinase inhibitors, and p53. In each case some knowledge of the protein's structure and function should allow for the design of a dominant negative mutant or, in the case of tumor suppressor genes, constitutively active gene products.
A recent example of this strategy involves making a site-directed, nonphosphorylatable mutant of Rb whose expression blocks SMC cell cycle progression in vitro and restenosis in vivo (28). Another potentially powerful gene therapy strategy for inhibiting the proliferation of vascular smooth muscle cells after injury is to deliver a gene that encodes a local diffusible inhibitor of growth. Such a strategy has a theoretical advantage over other approaches because the molecule produced is diffusible, and so the antiproliferative effects can be evident in cells that do not contain the transgene.
The ability to modify the growth of a population of cells in which perhaps only 10% or less is making the inhibitor relaxes the need to obtain complete gene transfer to all the target cells. Numerous inhibitor molecules would be tempting candidates for this approach. Because SMC proliferation appears to be regulated in part by endothehialproduced nitric oxide levels (33), the overexpression of nitric oxide synthase in areas of vascular injury, as has been recently demonstrated, provides an effective inhibition of proliferation (34) . Increasing local NO levels may have additional benefits besides inhibiting SMC prolifera- tion, because nitric oxide also inhibits platelet aggregation and is a vasodilator. Yet another gene therapy strategy for inhibiting injury-induced SMC proliferation is to deliver a gene that can convert an innocuous drug to a toxic metabolite. For example, one well-characterized approach for negative selection involves transfer of the herpes simplex virus thymidine kinase (HSV-tk)gene.
Cells expressing the HSV-tk gene when exposed to ganciclovir are capable of efficiently phosphorylating ganciclovir to produce a nucleoside analog that can be incorporated into the elongating DNA chain, but once incorporated causes chain termination and thereby aborts DNA synthesis. Hence the combination of HSV-tk gene expression coupled with exposure to ganciclovir results in cessation of cell growth (35) (36) (37) (38) .
That such strategies may be useful in the treating restenosis is evident by several recent reports using an adenovirus encoding HSV-tk to inhibit SMC proliferation after balloon injury in the pig femoral (39) and the rat carotid (40, 41) artery. In each case treatment reduced the resulting neointimal lesion by approximately 50%. An example of this strategy is shown in Fig. 3 antimetabolite. This strategy of a "pro-drug" gene therapy approach has a unique advantage from the standpoint of human safety in that the antiproliferative effects could be rapidly terminated by withdrawal of either ganciclovir or 5-fluorocytosine, even though the gene might continue to express its gene product for days or weeks longer. Nonetheless, all these strategies, from expression of dominant negative growth factor receptors to inhibition of cell cycle or the production of toxic nucleotides with a pro-drug strategy, represent general approaches to inhibition of cell proliferation. None of these strategies are specific or selective for vascular smooth muscle cells. As such, an important caveat for all such strategies is that the inhibition of growth could potentially extend to both the (59, 60) .
LOCAL DELIVERY OF VECTOR TO THE THERAPEUTIC TARGET
In addition to issues of viral gene product expression, the means of delivering the recombinant adenovirus to the site of vascular injury remains problematic.
At present there is no perfect flow-through catheter that will allow good distal perfusion of myocardium while both delivering the viral vector (or any other therapeutic agent) in a site-specific manner and permitting subsequent retrieval of the therapeutic agent without the potential dangers of downstream leakage (61) .
Even if the ideal catheter existed, the problem is compounded because of the multiple side branches that exit from each of the coronary arteries to which viral vectors would be delivered.
These side branches would provide a low resistance pathway for viral leakage and subsequent systemic tissue infection.
Although the virus delivered to these other tissues would presumably be significantly diluted, systemic viral delivery must still be considered a potential complication of gene therapy when a viral vector is used for gene delivery. This might be particularly troubling with transgenes that encode for toxic gene products. There are molecular-based approaches that can potentially be used to minimize the problem of systemic viral delivery.
For example, tissue-specific expression may be achieved by using a smooth muscle-specific promoter to drive the transgene.
In addition, as more is known about the specific interactions between adenoviral surface proteins and the high-affinity cell surface receptor, it may be possible to construct adenoviruses with a defined cell tropism. Recent evidence suggests that such a strategy may already be possible for retroviral constructs (62).
ISSUES TO BE RESOLVED
Having begun with the relatively simple proposition of trying to manipulate SMC proliferation with gene therapy, it is clear that a multitude of options exist. Choices need to be made about which delivery system will prove most effective: pure DNA, liposomes, HVJ-hiposomes, adenovirus, or others. In addition, choices must be made as to whether to use a dominant negative transgene, a gene that encodes a secreted toxin, or an antisense ohigonucleotide. For both of these issues, however, it is likely that more than one delivery system and more than one transgene (or oligonucleotide) will be required for the diverse applications that will undoubtedly evolve. Unfortunately, SMC proliferation is only one of several important aspects of the restenosis process. It remains unclear in the case of the human lesion whether proliferation is as critical as other processes, such as inflammatory cell recruitment, platelet adherence and aggregation, thrombus formation, or vascular remodeling.
To further complicate the situation, it is possible that these multiple potential mechanisms might be initiated by some common factor. For example, the initial migration and proliferation of SMCs may ultimately be responsible for the recruitment of other cell types (such as inflammatory cells) into the lesion or for the secretion of factors that lead to vascular remodeling.
Several approaches to the complex array of factors contributing to the restenosis process can be considered. Clearly some gene products, such as nitric oxide synthase, may affect more than one potential mechanism. One appealing possibility is to use a "cocktail" approach to locally express a variety of gene products, each aimed at different aspects of restenosis.
In this regard, a mixture of different adenoviruses or, because the present insert capacity of adenovirus is 7 Kb (63), an adenoviral encoding two or more gene products might prove fruitful.
OTHER THERAPEUTIC APPLICATIONS OF GENE TRANSFER TO THE VESSEL WALL
Although we have concentrated on the utility of gene therapy for the treatment of restenosis, other vascular applications exist. The modification of vascular grafts in the operative setting would be particularly appealing (23, 64, 65). Thus, arterial or vein grafts could be harvested and exposed, ex vivo, to either ohigonucleotides or recombinant adenoviruses with the hope of altering graft function. One goal would be to try to inhibit the development of a neointimal layer in vein grafts, which appears histologically similar to what is seen in restenosis and is thought to contribute to graft failure. Preliminary evidence suggests that such an approach may work. Thus, ex vivo genetic alteration of vein grafts by HVJ-liposome-mediated delivery of antisense ohigonucleotides to PCNA and cdc2 kinase were reported to make the grafts more resistant to neointimal formation, as well as to atherosclerotic changes, when the animals were exposed to an atherogenic diet (64) . It may also be possible in the future to make grafts less thrombogenie by the expression of molecules such as t-PA or hirudin. Similarly, inflammatory cell recruitment and retention in the graft may be altered by the overexpression of the soluble form of adhesion molecules such as VCAM or ICAM (65) .
In another potential application of gene therapy, the vascular graft might be modified to produce high levels of secreted angiogenic factors, which in turn could possibly stimulate the development of collateral growth in the coronary vasculature supplied by the graft. As such, ex vivo transfection of a vein graft with the genes encoding either VEGF or FGF-2 may provide a strategy that can significantly enhance collateral flow to ischemic myocardium.
NONTHERAPEUTIC USES OF GENE TRANSFER TO THE VESSEL WALL
In addition to the treatment of various vascular disorders, gene transfer techniques can serve as useful tools to complement our understanding of a variety of vascular diseases. The ability to genetically modify a region of the vessel wall provides in essence a "somatic transgenic"
animal, which allows the investigator to probe the role of a candidate gene in a disease process.
For such complicated diseases as atherosclerosis, which are not easily modeled in an in vitro situation and do not naturally occur in murine species, the power of gene transfer techniques become clear. As we have already discussed, transfer of genes encoding polypeptide growth factors into neointimal cells ascertained the role of these factors in SMC proliferation.
Also, similar types of experiments have demonstrated a role of TGF3 in matrix secretion in restenosis lesions (66) . In each of the previously mentioned cases, immunohistochemical data localized these gene products to the injured vessel wall. However, the ability to overexpress these factors locally helped confirm their pathogenic role. As such, one can begin to satisfy Koch's postulates, at least in animal models of vascular disease.
In addition to the restenosis lesion, gene products that contribute to the development of atherosclerosis can be studied.
As mentioned previously, it may be possible to assess directly the role of various adhesion molecules on atherosclerosis.
Direct 
